FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133149289> ?p ?o ?g. }

• W2133149289 endingPage "1889" @default.
• W2133149289 startingPage "1883" @default.
• W2133149289 abstract "The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).Patients ≥18 years old with histologically/cytologically confirmed stage IIIB/IV EGFR mutation-positive NSCLC and Eastern Cooperative Oncology Group performance status 0-2 were randomized 1:1 to receive erlotinib (oral; 150 mg once daily until progression/unacceptable toxicity) or GP [G 1250 mg/m(2) i.v. days 1 and 8 (3-weekly cycle); P 75 mg/m(2) i.v. day 1, (3-weekly cycle) for up to four cycles]. Primary end point: investigator-assessed progression-free survival (PFS). Other end points include objective response rate (ORR), overall survival (OS), and safety.A total of 217 patients were randomized: 110 to erlotinib and 107 to GP. Investigator-assessed median PFS was 11.0 months versus 5.5 months, erlotinib versus GP, respectively [hazard ratio (HR), 0.34, 95% confidence interval (CI) 0.22-0.51; log-rank P < 0.0001]. Independent Review Committee-assessed median PFS was consistent (HR, 0.42). Median OS was 26.3 versus 25.5 months, erlotinib versus GP, respectively (HR, 0.91, 95% CI 0.63-1.31; log-rank P = .607). ORR was 62.7% for erlotinib and 33.6% for GP. Treatment-related serious adverse events (AEs) occurred in 2.7% versus 10.6% of erlotinib and GP patients, respectively. The most common grade ≥3 AEs were rash (6.4%) with erlotinib, and neutropenia (25.0%), leukopenia (14.4%), and anemia (12.5%) with GP.These analyses demonstrate that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965)." @default.
• W2133149289 created "2016-06-24" @default.
• W2133149289 creator A5003748485 @default.
• W2133149289 creator A5004145316 @default.
• W2133149289 creator A5004928583 @default.
• W2133149289 creator A5013279525 @default.
• W2133149289 creator A5017251382 @default.
• W2133149289 creator A5027922054 @default.
• W2133149289 creator A5027984973 @default.
• W2133149289 creator A5028624269 @default.
• W2133149289 creator A5029411467 @default.
• W2133149289 creator A5038306289 @default.
• W2133149289 creator A5044185224 @default.
• W2133149289 creator A5045634907 @default.
• W2133149289 creator A5052876946 @default.
• W2133149289 creator A5055282224 @default.
• W2133149289 creator A5057523100 @default.
• W2133149289 creator A5057704753 @default.
• W2133149289 creator A5058876513 @default.
• W2133149289 creator A5062072699 @default.
• W2133149289 creator A5074092905 @default.
• W2133149289 creator A5077782269 @default.
• W2133149289 creator A5080952859 @default.
• W2133149289 creator A5086564929 @default.
• W2133149289 date "2015-09-01" @default.
• W2133149289 modified "2023-10-14" @default.
• W2133149289 title "First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study" @default.
• W2133149289 cites W1998499306 @default.
• W2133149289 cites W2021432503 @default.
• W2133149289 cites W2030864655 @default.
• W2133149289 cites W2055597038 @default.
• W2133149289 cites W2095618958 @default.
• W2133149289 cites W2096198395 @default.
• W2133149289 cites W2111662961 @default.
• W2133149289 cites W2132157071 @default.
• W2133149289 cites W2132870547 @default.
• W2133149289 cites W2138297714 @default.
• W2133149289 cites W2143859186 @default.
• W2133149289 cites W2159717588 @default.
• W2133149289 cites W2160982674 @default.
• W2133149289 cites W2161817637 @default.
• W2133149289 cites W2166084034 @default.
• W2133149289 cites W2167934111 @default.
• W2133149289 cites W2168841302 @default.
• W2133149289 cites W2171139285 @default.
• W2133149289 doi "https://doi.org/10.1093/annonc/mdv270" @default.
• W2133149289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26105600" @default.
• W2133149289 hasPublicationYear "2015" @default.
• W2133149289 type Work @default.
• W2133149289 sameAs 2133149289 @default.
• W2133149289 citedByCount "580" @default.
• W2133149289 countsByYear W21331492892014 @default.
• W2133149289 countsByYear W21331492892015 @default.
• W2133149289 countsByYear W21331492892016 @default.
• W2133149289 countsByYear W21331492892017 @default.
• W2133149289 countsByYear W21331492892018 @default.
• W2133149289 countsByYear W21331492892019 @default.
• W2133149289 countsByYear W21331492892020 @default.
• W2133149289 countsByYear W21331492892021 @default.
• W2133149289 countsByYear W21331492892022 @default.
• W2133149289 countsByYear W21331492892023 @default.
• W2133149289 crossrefType "journal-article" @default.
• W2133149289 hasAuthorship W2133149289A5003748485 @default.
• W2133149289 hasAuthorship W2133149289A5004145316 @default.
• W2133149289 hasAuthorship W2133149289A5004928583 @default.
• W2133149289 hasAuthorship W2133149289A5013279525 @default.
• W2133149289 hasAuthorship W2133149289A5017251382 @default.
• W2133149289 hasAuthorship W2133149289A5027922054 @default.
• W2133149289 hasAuthorship W2133149289A5027984973 @default.
• W2133149289 hasAuthorship W2133149289A5028624269 @default.
• W2133149289 hasAuthorship W2133149289A5029411467 @default.
• W2133149289 hasAuthorship W2133149289A5038306289 @default.
• W2133149289 hasAuthorship W2133149289A5044185224 @default.
• W2133149289 hasAuthorship W2133149289A5045634907 @default.
• W2133149289 hasAuthorship W2133149289A5052876946 @default.
• W2133149289 hasAuthorship W2133149289A5055282224 @default.
• W2133149289 hasAuthorship W2133149289A5057523100 @default.
• W2133149289 hasAuthorship W2133149289A5057704753 @default.
• W2133149289 hasAuthorship W2133149289A5058876513 @default.
• W2133149289 hasAuthorship W2133149289A5062072699 @default.
• W2133149289 hasAuthorship W2133149289A5074092905 @default.
• W2133149289 hasAuthorship W2133149289A5077782269 @default.
• W2133149289 hasAuthorship W2133149289A5080952859 @default.
• W2133149289 hasAuthorship W2133149289A5086564929 @default.
• W2133149289 hasBestOaLocation W21331492891 @default.
• W2133149289 hasConcept C121608353 @default.
• W2133149289 hasConcept C126322002 @default.
• W2133149289 hasConcept C143998085 @default.
• W2133149289 hasConcept C168563851 @default.
• W2133149289 hasConcept C197934379 @default.
• W2133149289 hasConcept C203092338 @default.
• W2133149289 hasConcept C207103383 @default.
• W2133149289 hasConcept C2776256026 @default.
• W2133149289 hasConcept C2778087573 @default.
• W2133149289 hasConcept C2779438470 @default.
• W2133149289 hasConcept C2780258809 @default.
• W2133149289 hasConcept C2909325608 @default.
• W2133149289 hasConcept C44249647 @default.

• next